Compounds > astragaloside IV
Page last updated: 2024-12-08

astragaloside IV

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth
FloraRankFlora DefinitionFamilyFamily Definition
Astragalusgenus[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID13943297
CHEMBL ID3121562
CHEBI ID65457
SCHEMBL ID21888259

Synonyms (33)

Synonym
beta-d-glucopyranoside, (3beta,6alpha,16beta,20r,24s)-20,24-epoxy-16,25-dihydroxy-3-(beta-d-xylopyranosyloxy)-9,19-cyclolanostan-6-yl
ast-iv
as-iv
C17799
1j6xa9ycfv ,
unii-1j6xa9ycfv
CHEBI:65457 ,
3-o-beta-d-xylopyranosyl-6-o-beta-d-glucopyranosylcycloastragenol
S3901
AKOS025311424
CHEMBL3121562
astragaloside iv [usp-rs]
astragaloside iv (constituent of astragalus) [dsc]
astrasieversianin xiv
astraversianin xiv
.beta.-d-glucopyranoside, (3.beta.,6.alpha.,16.beta.,20r,24s)-20,24-epoxy-16,25-dihydroxy-3-(.beta.-d-xylopyranosyloxy)-9,19-cyclolanostan-6-yl
HY-N0431
astragaloside iv, >98.0%
astragaloside iv, united states pharmacopeia (usp) reference standard
astragalosideiv
astragaloside iv, european pharmacopoeia (ep) reference standard
astragaloside iv 95%
(2r,3r,4s,5s,6r)-2-(((2ar,3r,4s,5as,5bs,7s,7ar,9s,11ar,12as)-4-hydroxy-3-((2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)tetradecahydro-1h,12h-cyclopenta[
(2r,3r,4s,5s,6r)-2-[[(1s,3r,6s,8r,9s,11s,12s,14s,15r,16r)-14-hydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hyd
SCHEMBL21888259
Q27133900
cyclosieversioside f
AS-19402
astramembrannin i;astragalin a
HMS3885E12
CCG-270470
(2r,3r,4s,5s,6r)-2-[[(1s,3r,8r,9s,11s,12s,14s,15r,16r)-14-hydroxy-15-[(2r,5s)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydrox
DTXSID801026063
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
EC 4.2.1.1 (carbonic anhydrase) inhibitorAn EC 4.2.1.* (hydro-lyases) inhibitor that interferes with the action of carbonic anhydrase (EC 4.2.1.1). Such compounds reduce the secretion of H(+) ions by the proximal kidney tubule.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
pro-angiogenic agentAny compound that promotes the growth of new blood vessels from pre-existing vessels.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triterpenoid saponinA terpene glycoside in which the terpene moiety is a triterpenoid.
pentacyclic triterpenoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID1756148Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as reduction in STAT3 mRNA expression level administered for 10 consecutive days by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1072524Antiviral activity against Duck Hepatitis B virus infected in duckling assessed as decrease in DHBV level in serum at 120 mg/kg dosed through liquid diet for 10 days administered started on day 7 post-infection2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1414022Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in index of right ventricular hypertrophy by measuring ratio of right ventricular/(left ventricular + septum) weight at 50 mg/kg, ip admini2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756166Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced Smad4 mRNA expression level by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756172Induction of cell cycle arrest in human BMSCs overexpressing miR-124-3p.1 assessed as accumulation of cells at S phase at 160 mg/ml under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756163Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced Smad4 protein expression level by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756169Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as increase in Conn.D of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1156795Retention time of the compound by chromatography2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1756171Induction of cell cycle arrest in human BMSCs overexpressing miR-124-3p.1 assessed as decrease in cells at G0/G1 phase at 160 mg/ml under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414025Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat pulmonary arterial ring assessed as increase in relaxation of pulmonary artery ring at 50 uM treated after phenylephrine-induced vasoconstriction measured at 1 2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756174Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in alkaline phosphatase activity at 160 mg/ml incubated for 21 days under osteogenic conditions by ELISA2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756159Induction of osteogenic differentiation in human BMSCs assessed as increase in alkaline phosphatase activity incubated for 21 days under osteogenic conditions by ELISA2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414027Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in serum endothelin levels at 10 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 weeks2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756154Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as decrease in Tb.Sp of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756180Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced OCN mRNA expression level at 160 mg/ml by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756147Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as reduction in miR-124-3p.i mRNA expression level administered for 10 consecutive days by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756157Induction of cell cycle arrest in human BMSCs assessed as accumulation of cells at S phase under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414038Inhibition of hypoxia-induced proliferation of Sprague-Dawley rat PASMC at 10 uM preincubated for 10 mins followed by hypoxia induction and measured after 24 hrs by CCK8 assay2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756155Induction of osteogenic differentiation in human BMSCs assessed as increase in cell viability incubated for 72 hrs under osteogenic conditions by MTT assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756149Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as reduction in STAT3 protein expression level administered for 10 consecutive days by Western blotting analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756160Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced matrix mineralization by measuring calcium deposition by Alizarin Red S staining-based microscopic analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756176Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced RUNX2 protein expression level at 160 mg/ml by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756165Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced OCN mRNA expression level by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1156800Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1756181Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced Smad4 mRNA expression level at 160 mg/ml by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1156796Binding affinity to Bcl-xL (unknown origin)2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1414017Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in mean pulmonary arterial pressure at 10 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured afte2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756179Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced RUNX2 mRNA expression level at 160 mg/ml by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414020Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in mean pulmonary arterial pressure at 50 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured afte2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756173Induction of cell cycle arrest in human BMSCs overexpressing miR-124-3p.1 assessed as accumulation of cells at G2/M phase at 160 mg/ml under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1072525Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV e antigen secretion at 200 ug/ml after 9 days by ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1414034Tmax in chronic hypoxia-induced pulmonary hypertension model of Sprague-Dawley rat at 50 mg/kg, ip after 30 to 600 mins by HPLC analysis2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414024Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat pulmonary arterial ring assessed as increase in relaxation of pulmonary artery ring at 10 uM treated after phenylephrine-induced vasoconstriction measured at 102018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756158Induction of cell cycle arrest in human BMSCs assessed as accumulation of cells at G2/M phase under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756152Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as increase in Tb.Th of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756178Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced Smad4 protein expression level at 160 mg/ml by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414023Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat pulmonary arterial ring assessed as increase in relaxation of pulmonary artery ring at 10 uM treated after phenylephrine-induced vasoconstriction measured at 1 2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414030Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in serum angiotensin-2 levels at 50 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 we2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414018Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in right ventricular pressure at 10 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 we2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756151Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as increase in Tb.N of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414019Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in index of right ventricular hypertrophy by measuring ratio of right ventricular/(left ventricular + septum) weight at 10 mg/kg, ip admini2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756153Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as increase in BMD of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414021Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in right ventricular pressure at 50 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 we2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414032Protective effect against chronic hypoxia-induced pulmonary hypertension in ip dosed Sprague-Dawley rat assessed as decrease in serum IL-6 levels administered every other day at 10 mins prior to induction of hypoxia and measured after 2 weeks by ELISA2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756170Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in cell viability at 160 mg/ml incubated for 72 hrs under osteogenic conditions by MTT assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756168Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as alleviation of bone injury administered for 10 consecutive days by HE staining based assay2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414028Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in serum angiotensin-2 levels at 10 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 we2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756177Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced OCN protein expression level at 160 mg/ml by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756175Induction of osteogenic differentiation in human BMSCs overexpressing miR-124-3p.1 assessed as increase in osteogenic medium-induced matrix mineralization by measuring calcium deposition at 160 mg/ml by Alizarin Red S staining-based microscopic analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756164Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced RUNX2 mRNA expression level by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756156Induction of cell cycle arrest in human BMSCs assessed as decrease in cells at G0/G1 phase under osteogenic conditions by PI staining based flow cytometric analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414031Protective effect against chronic hypoxia-induced pulmonary hypertension in ip dosed Sprague-Dawley rat assessed as decrease in serum TNF-alpha levels administered every other day at 10 mins prior to induction of hypoxia and measured after 2 weeks by ELIS2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1072526Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as decrease in HBV surface antigen secretion at 200 ug/ml after 9 days by ELISA2014European journal of medicinal chemistry, Mar-21, Volume: 75A review of non-nucleoside anti-hepatitis B virus agents.
AID1756167Induction of osteogenic differentiation in human BMSCs assessed as down regulation of miR-124-3p.1 mRNA expression level at 160 mg/ml under osteogenic condition by RT-qPCR analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414035Cmax in chronic hypoxia-induced pulmonary hypertension model of Sprague-Dawley rat at 10 mg/kg, ip after 30 to 600 mins by HPLC analysis2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414036Tmax in chronic hypoxia-induced pulmonary hypertension model of Sprague-Dawley rat at 10 mg/kg, ip after 30 to 600 mins by HPLC analysis2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414029Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat assessed as decrease in serum endothelin levels at 50 mg/kg, ip administered every other day at 10 mins prior to induction of hypoxia and measured after 2 weeks2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756150Induction of tibial bone defect regeneration in ip dosed Lewis rat assessed as increase in BV/TV of tibial bone administered for 10 consecutive days by microcomputed tomography method2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1756162Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced OCN protein expression level by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1414026Protective effect against chronic hypoxia-induced pulmonary hypertension in Sprague-Dawley rat pulmonary arterial ring assessed as increase in relaxation of pulmonary artery ring at 50 uM treated after phenylephrine-induced vasoconstriction measured at 102018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1756161Induction of osteogenic differentiation in human BMSCs assessed as increase in osteogenic medium-induced RUNX2 protein expression level by Western blot analysis2021Journal of natural products, 02-26, Volume: 84, Issue:2
Astragaloside IV Improves Tibial Defect in Rats and Promotes Proliferation and Osteogenic Differentiation of hBMSCs through MiR-124-3p.1/STAT3 Axis.
AID1873249Anti-obesity activity in male C57BL/6 mouse model of high-fat diet induced obesity assessed as body weight change at 25 mg/kg, ip administered once a day for 13 weeks relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
AID1414037Inhibition of hypoxia-induced proliferation of Sprague-Dawley rat PASMC at 50 uM preincubated for 10 mins followed by hypoxia induction and measured after 24 hrs by CCK8 assay2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
AID1414033Cmax in chronic hypoxia-induced pulmonary hypertension model of Sprague-Dawley rat at 50 mg/kg, ip after 30 to 600 mins by HPLC analysis2018MedChemComm, Oct-01, Volume: 9, Issue:10
Protective effects of astragaloside IV against hypoxic pulmonary hypertension.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
7,8-dihydroxyflavone
7,8-dihydroxyflavone : A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A dihydroxyflavone that is flavone substituted by hydroxy groups at positions 7 and 8. A naturally occurring flavonoid produced by several plants, including the weed Tridax procumbens (coalbuttons or tridax daisy) and the tree Godmania aesculifolia, In animal models, it has shown efficacy against several diseases of the nervous system, including Alzheimer's, Parkinson's, and Huntington's.		3.5110dihydroxyflavoneantidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist
protocatechualdehyde
protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure		3.1910dihydroxybenzaldehyde
glycyrrhetinic acid
[no description available]		3.5110cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
aloe emodin
aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.		3.1910aromatic primary alcohol;
dihydroxyanthraquinone		antineoplastic agent;
plant metabolite
chrysophanic acid
chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.		3.1910dihydroxyanthraquinoneanti-inflammatory agent;
antiviral agent;
plant metabolite
oleanolic acid
[no description available]		3.5110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
physcione
physcione: structure. physcion : A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources.		3.1910dihydroxyanthraquinoneanti-inflammatory agent;
antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
hepatoprotective agent;
metabolite
nitazoxanide
nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug		3.1910benzamides;
carboxylic ester
lamivudine
[no description available]		3.1910monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
narciclasine
narciclasine: antitumor alkaloid from bulbs of Narcissus species		3.5110phenanthridinesmetabolite
isoalantolactone
isoalantolactone: RN given refers to (3aR-(3aalpha,4aalpha,8abeta,9aalpha))-isomer; structure. isoalantolactone : A sesquiterpene lactone of the eudesmanolide group. It has been isolated from Inula helenium.		3.5110eudesmane sesquiterpenoid;
sesquiterpene lactone		antifungal agent;
apoptosis inducer;
plant metabolite
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		3.5110dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
asperuloside
asperuloside : A iridoid monoterpenoid glycoside isolated from Galium verum.		3.5110acetate ester;
beta-D-glucoside;
gamma-lactone;
iridoid monoterpenoid;
monosaccharide derivative		metabolite
diphyllin
diphyllin: extract of Cleistanthus collinus (Roxb), a highly poisonous plant; do not confuse with diphyllin or diphylline which is the main heading AMINOPHYLLINE; do not confuse with the theophylline derivative DYPHYLLINE		3.5110lignan
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.1107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
tanshinone
tanshinone: from root of Salvia miltiorrhiza Bunge; RN given refers to tanshinone I; cardioprotective agent and neuroprotective agent		3.5110abietane diterpenoidanticoronaviral agent
celastrol
[no description available]		3.5110monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
glabridin
[no description available]		3.5110hydroxyisoflavansantiplasmodial drug
oleanolic acid 3-acetate
oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer		2.110
helioxanthin
helioxanthin: structure in first source. helioxanthin : A furonaphthodioxole that is furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7(9H)-one substituted by a 1,3-benzodioxol-5-yl group at posiiton 10. It is a inhibitor of HBV, HCV and HSV-1 viruses.		3.1910benzodioxoles;
furonaphthodioxole;
lignan		anti-HBV agent;
antineoplastic agent;
plant metabolite
withaferin a
withaferin A: an antiestrogen and phytogenic antineoplastic agent isolated from leaves of Withania somnifera Dun.; structure. withaferin A : A withanolide that is 5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione substituted by hydroxy groups at positions 4 and 27 (the 4beta,5beta,6beta,22R stereoisomer). Isolated from Physalis longifolia, it exhibits cytotoxic activity.		3.511027-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide		antineoplastic agent;
apoptosis inducer
hyperforin
hyperforin: a prenylated acylphloroglucinol derivative; antibiotic component of novoimanine; psychoactive agent in St. John's wort; Russian; structure;. hyperforin : A cyclic terpene ketone that is a prenylated carbobicyclic acylphloroglucinol derivative produced by St. John's Wort, Hypericum perforatum.		3.5110
chrysophanol 8-o-glucoside
chrysophanol 8-O-glucoside: has anti-hepatitis B virus activity; also has antiplatelet and anticoagulant activities; isolated from Rheum palmatum. chrysophanol 8-O-beta-D-glucoside : A beta-D-glucoside in which the aglycone species is chrysophanol, the glycosidic linkage being to the hydroxy group at C-8.		3.1910beta-D-glucoside;
monohydroxyanthraquinone
ononin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
monosaccharide derivative		plant metabolite
ganoderic acid a
[no description available]		3.6820triterpenoid
ganoderiol f
ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source		2.110triterpenoid
dihydrochelerythrine
dihydrochelerythrine: trypanocidal and antileishmanial dihydrochelerythrine derivative from Garcinia lucida; structure in first source		3.1910benzophenanthridine alkaloid
bay 41-4109
BAY 41-4109: structure in first source		3.1910
hbf 0259
[no description available]		3.1910
formononetin
[no description available]		3.68204'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
luteolin
[no description available]		2.1103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
apigetrin
apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative		antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
butein
[no description available]		3.5110chalcones;
polyphenol		antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		3.1910dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
3',4',7-trihydroxyisoflavone
3',4',7-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source. 3',4',7-trihydroxyisoflavone : A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'.		3.51107-hydroxyisoflavonesantineoplastic agent;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite
corylin
corylin: from Psoralea corylifolia (Leguminosae), has osteoblastic proliferation stimulating activity; structure in first source		3.5110
calycosin-7-o-beta-d-glucopyranoside
calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304
SPD-304: structure in first source		2.110
3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-one
3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one: metabolite of ellagic acid		3.5110coumarinsgeroprotector
helioxanthin 8-1
helioxanthin 8-1: an antiviral agent; structure in first source		3.1910
panduratin a
panduratin A: isolated from Kaempferia pandurata; structure in first source		3.5110diarylheptanoidmetabolite
artesunate
artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether		3.1910artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid		antimalarial;
antineoplastic agent;
ferroptosis inducer
lipstatin
lipstatin: isolated from Streptomyces toxytricini; inhibitor of pancreatic lipase; structure given in first source		3.5110
leucamide a
leucamide A: a cytotoxic heptapeptide from the Australian sponge Leucetta microraphis; structure in first source		3.1910
diosgenin glucoside
diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source. diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.		2.110hexacyclic triterpenoid;
monosaccharide derivative;
spiroketal;
sterol 3-beta-D-glucoside		metabolite
rosamultin
rosamultin: isolated from roots of Rosa multiflora; RN not in Chemline 3/87; RN from Chem Abstracts Index Guide 1985		3.1910
ganoderic acid f
ganoderic acid F: isolated from Ganoderma lucidum; structure in first source		2.110triterpenoid
2-hydroxybenzoyl-n-(5-chlorothiazol-2-yl)amide
2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide: an antiviral agent effective against hepatitis B virus; structure in first source		3.1910
ganoderic acid c2
ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source		2.110triterpenoid
alisol f
[no description available]		3.1910
alisol a 24-acetate
alisol A 24-acetate: isolated from Alismatis Rhizoma; structure in first source		3.1910
ConditionIndicatedRelationship StrengthStudiesTrials
Hepatitis B Virus Infection
[description not available]		03.0110
Hepatitis B
INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.		03.0110
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		03.3310